438.60SEK-0.14%Mkt Cap: 153.14B SEKP/E: 167.68Last update: 2026-05-13
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates…
Industry Peers
Drug Manufacturers - Specialty & Genericloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)167.68
P/E (Forward)28.36
PEG0.33
P/B3.78
P/S5.29
EV/EBITDA14.63
EV/Revenue5.89
EPS (TTM)2.60
EPS (Forward)15.55
Cash Flow & Leverage
FCF Yield2.69%
FCF Margin14.25%
Operating CF8.56B SEK
CapEx (TTM)3.15B SEK
Net Debt/EBITDA1.55
Net Debt18.12B SEK
Technical
SMA 50402.50 (+9.0%)
SMA 200345.45 (+27.0%)
Beta0.26
S&P 52W Chg24.23%
Avg Vol (30d)396.01K
Avg Vol (10d)470.98K
Technical Indicators
RSI (14)63.8
MACD11.9143
MACD Signal10.5860
MACD Hist.+1.3283
BB Upper453.69 SEK
BB Middle422.07 SEK
BB Lower390.45 SEK
BB Width14.98%
ATR (14)10.76 SEK
Vol Ratio (20d)0.38x
52W Range
261.2094% of range450.00
52W High450.00 SEK
52W Low261.20 SEK
Profitability
Gross Margin77.86%
EBITDA Margin40.29%
Profit Margin1.69%
Oper. Margin26.59%
ROE1.27%
ROA0.71%
Revenue Growth11.10%
Earnings Growth49.60%
Balance Sheet
Debt/Equity0.30
Current Ratio0.70
Quick Ratio0.47
Book Value/Sh116.75 SEK
Cash/Share2.718 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.345.85M
Float221.93M
Insiders10.05%
Institutions74.37%
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)456.77 SEK
Target Range308.00 SEK – 530.00 SEK
# Analysts13
Company
Market Cap153.14B SEK
Enterprise Value170.64B SEK
Revenue (TTM)28.96B SEK
Gross Profit21.99B SEK
Net Income (TTM)478.00M SEK
Revenue/Share83.96 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees2.0K
Last Price438.60 SEK
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0000872095